Kineta, Inc. (NASDAQ:KA – Get Free Report) was the recipient of a significant drop in short interest during the month of September. As of September 15th, there was short interest totalling 200 shares, a drop of 99.3% from the August 31st total of 28,500 shares. Based on an average daily volume of 600 shares, the short-interest ratio is currently 0.3 days.
Kineta Trading Down 4.8 %
NASDAQ KA opened at $0.60 on Friday. The stock has a market cap of $7.35 million, a P/E ratio of -0.40 and a beta of 0.46. Kineta has a fifty-two week low of $0.33 and a fifty-two week high of $5.39. The stock has a 50 day simple moving average of $0.65 and a two-hundred day simple moving average of $0.59. The company has a debt-to-equity ratio of 0.05, a quick ratio of 0.14 and a current ratio of 0.14.
Kineta (NASDAQ:KA – Get Free Report) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($0.20) EPS for the quarter.
Hedge Funds Weigh In On Kineta
About Kineta
Kineta, Inc is a clinical-stage biotechnology company with a focus on developing immunotherapies that transform patients' lives. It focuses on developing potentially differentiated immunotherapies that address the challenges with current cancer therapy. The company's immuno-oncology pipeline includes KVA12123, a VISTA blocking immunotherapy in development as a twice weekly monoclonal antibody (mAb) infusion drug.
See Also
- Five stocks we like better than Kineta
- The How And Why of Investing in Oil Stocks
- Rocket Lab Stock Soars: Should Investors Chase the Rally?
- What is a Bond Market Holiday? How to Invest and Trade
- KB Home Slips After Earnings: What’s Next for Homebuilders?
- There Are Different Types of Stock To Invest In
- Micron Stock Soars as AI Demand Fuels Big Q4 Earnings Beat
Receive News & Ratings for Kineta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kineta and related companies with MarketBeat.com's FREE daily email newsletter.